Author

Blake M. Paterson

Observed names: B M Paterson, B. M. PATERSON, B. M. Paterson, B.M. Paterson, Blake Paterson

Observed institutions: Albert Einstein College of Medicine, Beth Israel Deaconess Medical Center, Mayo Clinic, Montefiore Medical Center, Harvard University, Johns Hopkins University, Eli Lilly (United States), Thomas Jefferson University Hospital, Johns Hopkins Medicine, Cerecor (United States), Indiana University School of Medicine

OpenAlex ID: A5080901262

The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT‐1001 in coeliac disease subjects: a proof of concept study

2007 · B. M. PATERSON, K. M. LAMMERS, et al. · Alimentary Pharmacology & Therapeutics · 279

PDF

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study

2012 · C. P. Kelly, P. H. R. Green, et al. · Alimentary Pharmacology & Therapeutics · 201

A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge

2012 · Daniel A Leffler, C P Kelly, et al. · The American Journal of Gastroenterology · 186

Larazotide acetate regulates epithelial tight junctions in vitro and in vivo

2012 · Shobha Gopalakrishnan, Malarvizhi Durai, et al. · Peptides · 117

Protein Kinase C Alpha Expression in Breast and Ovarian Cancer

2004 · Michael Lahn, Gabriele Köhler, et al. · Oncology · 96

Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selectiveN‐methyl‐D‐aspartate receptor antagonist

2015 · Rachel Garner, Shobha Gopalakrishnan, et al. · Pharmacology Research & Perspectives · 42

PDF

Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer

2004 · Michael Lahn, Chen Su, et al. · Clinical Lung Cancer · 42

A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior

2019 · Jermaine D. Jones, Shanna Babalonis, et al. · Addiction Biology · 24

Protein kinase C‐α in prostate cancer

2004 · M. Lahn, K. Sundell, et al. · British Journal of Urology · 23

Effect of Memantine on Cough Reflex Sensitivity: Translational Studies in Guinea Pigs and Humans

2014 · Peter V. Dicpinigaitis, Brendan J. Canning, et al. · Journal of Pharmacology and Experimental Therapeutics · 21

The role of protein kinase C-alpha (PKC-α) in malignancies of the gastrointestinal tract

2003 · M. Lahn, B.M. Paterson, et al. · European Journal of Cancer · 21

The role of protein kinase C-α in malignancies of the nervous system and implications for the clinical development of the specific PKC-α inhibitor aprinocarsen (Review)

2004 · Michael Lahn, Karen Sundell, et al. · Oncology Reports · 8

585 A Randomized, Double-Blind Study of AT-1001 for the Prevention of Celiac Disease Activation with Gluten Challenge

2008 · Daniel A. Leffler, Ciaran Kelly, et al. · Gastroenterology · 4

Inhibitors of Intestinal Barrier Dysfunction

2008 · Blake M. Paterson, Jerrold R. Turner · KARGER eBooks · 3

Commentary: larazotide acetate ‐ an exciting new development for coeliac patients? Authors’ reply

2013 · C. P. Kelly, P. H. R. Green, et al. · Alimentary Pharmacology & Therapeutics · 1

Inhibition of Zonulin‐mediated Increased Intestinal Permeability Blocks Progression From Pre‐clinical Autoimmunity to Type 1 Diabetes in Bb/wor Rats

2005 · Anna Sapone, Klara Margaretten, et al. · Journal of Pediatric Gastroenterology and Nutrition · 1

Evaluation of CERC-501, a selective kappa opioid antagonist in preclinical models of alcoholism

2017 · Donald R. Gehlert, Linda Rorick-Kehn, et al. · Drug and Alcohol Dependence

Larazotide Acetate (AT-1001) Prevents Immunologic Changes Induced by Gluten Challenge in Patients with Celiac Disease

2008 · Daniel Leffler, Mark David Pescovitz, et al. · The American Journal of Gastroenterology

Larazotide Acetate (AT-1001) Inhibits Epithelial Permeability Induced by TNF-α and IL-4

2008 · Niranjan Pandey, Kelly Kitchens, et al. · The American Journal of Gastroenterology

T1269 Effects of Synthetic Zot Peptide Analog AT-1002 and Inhibitor AT-1001 On Gluten Induced Alterations in Barrier Function and Macrophage Recruitment in HLA-HCD4/DQ8 Mice

2008 · Elena F. Verdu, Jane Natividad, et al. · Gastroenterology

F.52. A Tight Junction Permeability Inhibitor Peptide AT-1001, Inhibits TNF-α Production from Human PBMC

2008 · Neil Poloso, Rosa Carrasco, et al. · Clinical Immunology

Effects of a Novel Mucosal Adjuvant AT-1002 on Immune Responses in Mice Immunized Intranasally with Ovalbumin

2007 · Amir Tamiz, Niranjan Pandey, et al. · Clinical Immunology

Works count: 23

Citation count: 1,070

H-index: 11

I10-index: 11